The AKT inhibitor ipatasertib in combination with abiraterone shows promising results in castration-resistant prostate cancer

Best Practice Nordic | Sep 2020 | ESMO 2020 |

Johann de Bono presented the first results from the phase III study IPATential150 at this year’s ESMO Virtual Congress 2020. In IPATential150 ipatasertib is given in combination with abiraterone to patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) who had not previously been treated for mCRPC. 40-50% of mCRPC patients have loss of PTEN, which leads to overactivation of the PI3K/AKT signaling pathway. Patients have a poor prognosis and it is also associated with an inferior effect of androgen receptor blockade. Co-primary endpoints are radiologically progression-free survival (rPFS) with the group with PTEN loss detected histologically and for the ITT group. The study showed a significant improvement of two months progression-free survival in the group with loss of PTEN, but not in the ITT population. It is too early to assess the overall survival in the study as data are not mature. In the iparsertib and abiraterone group, dose reduction was required in 40% of patients. Find more information: IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) ESMOs youtube-kanal: ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 study Latest news from ESMO20: [latest category="ESMO-2020" num="3]